Kytopen is an MIT startup developing a proprietary FlowfectTM technology for non-viral delivery of molecules into hard-to-transfect immune cells. The scalable FlowfectTM technology combines microfluidics and automation to make this process easier, faster, and cheaper than ever before. With the FlowfectTM automated cell engineering platform, Kytopen plans to enable new discoveries in biology that will lead to cost-effective cell and gene therapies.
- Paulo Garcia CEO and Co-Founder
- Cullen Buie Co-Founder
- James Hemphill Scientist
- Jessica Sido Scientist
- Rameech McCormack R&D Engineer